A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 3, 2005, Pages 127-136

  Cryer, Byron ^a   Binkley, Neil ^b   Simonelli, Christine ^c   Lewiecki, E Michael ^d   Lanza, Frank ^e   Chen, Erluo ^f   Petruschke, Richard A ^f   Mullen, Christine ^f   de Papp, Anne E ^f  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^d NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^e Houston Institute for Clinical Research   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adverse events; Alendronate; Biochemical markers; Once weekly; Oral solution; Tolerability; Upper gastrointestinal

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCIUM CARBONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; ERUCTATION; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PAIN; PALATABILITY; PEPTIC ULCER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; UPPER GASTROINTESTINAL TRACT;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL DISEASES; FEMALE; HUMANS; NAUSEA; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PHARMACEUTICAL SOLUTIONS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UPPER GASTROINTESTINAL TRACT;

EID: 27844478192     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1543-5946(05)80019-4     Document Type: Article

References (22)

1. Fosamax [package insert] 2005 Merck & Company Whitehouse Station, NJ
2. de Groen PC Lubbe DF Hirsch LJ et al. Esophagitis associated with the use of alendronate N Engl J Med 335 1996 1016-1021
3. Watts N Freedholm D Daifotis A The clinical tolerability profile of alendronate Int J Clin Pract Suppl 101 1999 51-61
4. Greenspan SL Harris ST Bone H et al. Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis Am Fam Physician 61 2000 2731-2736
5. Watts NB Treatment of osteoporosis with bisphosphonates Rheum Dis Clin North Am 27 2001 197-214
6. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Available at: http://www.wma.net/e/policy/b3.htm Accessed August 2005
7. Medical Dictionary for Regulatory Activities Available at http://www.meddramsso.com Accessed August 2005
8. Marubini E Valsecchi MG Analysing Survival Data from Clinical Trials and Observational Studies 1995 Wiley Chichester, UK 320-329
9. Newcombe R Interval estimation for the difference between independent proportions: Comparison of eleven methods [published correction appears in Stat Med 1999;18:1293] Stat Med 17 1998 873-890
10. Wong P Mukhopadhyay S Quan H Larson P Confidence intervals for between-treatment mean difference when analysis is on the log percent scale Presented at: Joint Statistical Meetings August 3-7 2003 San Francisco, California
11. Peter CP Handt LK Smith SM Esophageal irritation due to alendronate sodium tablets: Possible mechanisms Dig Dis Sci 43 1998 1998-2002
12. Peter CP Kindt MV Majka JA Comparative study of potential for bisphosphonates to damage gastric mucosa of rats Dig Dis Sci 43 1998 1009-1015
13. 21 CFR § 331.
14. Feldman M Barnett C Relationships between the acidity and osmolality of popular beverages and reported postprandial heartburn Gastroenterology 108 1995 125-131
15. Greenspan S Field-Munves E Tonino R et al. Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study Mayo Clin Proc 77 2002 1044-1052
16. Eisman JA Rizzoli R Roman-Ivorra J et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: Results of a randomized, double-blind, placebo-controlled study Curr Med Res Opin 20 2004 699-705
17. Lanza F Sahba B Schwartz H et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study Am J Gastroenterol 97 2002 58-64
18. Luckey M Kagan R Greenspan S et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis Menopause 11 2004 405-415
19. Sambrook PN Geusens P Ribot C et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International J Intern Med 255 2004 503-511
20. Rosen CJ Hochberg MC Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study J Bone Miner Res 20 2005 141-151
21. Schnitzer T Bone HG Crepaldi G et al. for the Alendronate Once-Weekly Study Group Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging (Milano) 12 2000 1-12
22. Rizzoli R Greenspan SL Bone G III et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis J Bone Miner Res 17 2002 1988-1996